Psilocybin toxicity: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
==Background ==
==Background ==
*A compound found in over 200 mushrooms that has mind altering properties similar to LSD.
*Commonly known as "magic mushrooms" or "shrooms". The mushroom are often taken recreationally for the euphoric and hallucinogenic effects. Typically grown in the Pacific Northwest and southern regions of the United States.
*For a typical dose (1mg) symptoms will last 1-3 hours.
*Low toxicity with LD50 of 280mg/kg
**Therapeutic index = 641
[[File:Psilocybe semilanceata.jpg|thumb|''Psilocybe semilanceata'']]
[[File:Psilocybe semilanceata.jpg|thumb|''Psilocybe semilanceata'']]
A compound found in over 200 mushrooms that has mind altering properties similar to LSD. Commonly known as "magic mushrooms" or "shrooms". The mushroom are often taken recreationally for the euphoric and hallucinogenic effects. Typically grown in the Pacific Northwest and southern regions of the United States. For a typical dose (1mg) symptoms will last 1-3 hours.
=== Toxicity ===
*Low
*280mg/kg
*Therapeutic index of 641


== Clinical Features==
==Clinical Features==
*Sensory/psychiatric
*Sensory/psychiatric
**Euphoria
**Euphoria
Line 37: Line 37:
*[[Urine drug screen]] if concerned about co-ingestion
*[[Urine drug screen]] if concerned about co-ingestion


== Management ==
==Management==
*Supportive care
*Supportive care
*Place patient in a calm and quiet environment
*Place patient in a calm and quiet environment
Line 49: Line 49:
*[[Drugs of abuse]]
*[[Drugs of abuse]]


== References ==
==References==
* Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101:131.
<references/>
* UpToDate
*  van Amsterdam J, Opperhuizen A, van den Brink W (2011). "Harm potential of magic mushroom use: a review" (PDF). Regulatory Toxicology and Pharmacology. 59 (3): 423–9. doi:10.1016/j.yrtph.2011.01.006. PMID 21256914.
*  Merck Index, 11th Edition, 7942
*  "Comparison of acute lethal toxicity of commonly abused psychoactive substances" (PDF). Addiction. 99 (6): 686–96. doi:10.1111/j.1360-0443.2004.00744.x. PMID 15139867.
*  Passie T, Seifert J, Schneider U, Emrich HM (2002). "The pharmacology of psilocybin". Addiction Biology. 7 (4): 357–64. doi:10.1080/1355621021000005937. PMID 14578010.
*"Comparison of acute lethal toxicity of commonly abused psychoactive substances" (PDF). Addiction. 99 (6): 686–96. doi:10.1111/j.1360-0443.2004.00744.x. PMID 15139867.
* Halpern JH1. "Hallucinogens and dissociative agents naturally growing in the United States." Pharmacol Ther. 2004 May;102(2):131-8.


[[Category:Toxicology]]
[[Category:Toxicology]]

Revision as of 04:12, 9 July 2017

Background

  • A compound found in over 200 mushrooms that has mind altering properties similar to LSD.
  • Commonly known as "magic mushrooms" or "shrooms". The mushroom are often taken recreationally for the euphoric and hallucinogenic effects. Typically grown in the Pacific Northwest and southern regions of the United States.
  • For a typical dose (1mg) symptoms will last 1-3 hours.
  • Low toxicity with LD50 of 280mg/kg
    • Therapeutic index = 641
Psilocybe semilanceata

Clinical Features

Differential Diagnosis

Drugs of abuse

Evaluation

Management

  • Supportive care
  • Place patient in a calm and quiet environment
  • Benzodiazepines for worsening tachycardia/hypertension or agitation

Disposition

  • Discharge when vitals normalize and clinically sober

See Also

References